Akademik Veri Yönetim Sistemi
DURMAZ E. (Yürütücü), GÜVEN M., KOCA D., MALİKOVA N., İKİTİMUR B.
Yükseköğretim Kurumları Destekli Proje, BAP Araştırma Projesi, 2019 - 2025
This study aims to evaluate the impact of adrenergic
beta-1 receptor (ADRB1) gene polymorphisms, on the hemodynamic response to
beta-blocker therapy and long-term cardiovascular outcomes in patients with
ST-segment elevation myocardial infarction (STEMI) treated with primary
percutaneous coronary intervention (pPCI).
A total of 173 STEMI patients who underwent pPCI and
received beta-blocker therapy were prospectively enrolled. Genetic analyses for
Ser49Gly and Arg389Gly polymorphisms were conducted. Hemodynamic parameters,
including blood pressure and heart rate, were measured; and long-term
outcomes were monitored.
Patients homozygous for Arg389 exhibited a significant
reduction in blood pressure following beta-blocker therapy, while Gly389 carriers
showed no significant changes. Similarly, patients with Ser49 had stronger
hemodynamic responses compared to Gly49 carriers. Despite these variations, no
significant differences were observed in long-term outcomes, including
mortality.
ADRB1 polymorphisms, influence the short-term
hemodynamic response to beta-blocker therapy in STEMI patients. However, these
genetic variations do not appear to significantly affect long-term
cardiovascular outcomes.
Key words: ST-segment elevation myocardial infarction, ADRB
gene polymorphism, beta-blocker